We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Compounder’s Recall Reignites Congressional Criticism of FDA
Compounder’s Recall Reignites Congressional Criticism of FDA
April 1, 2013
A recent recall by a New Jersey-based specialty pharmacy has reignited congressional criticism that the FDA is not doing enough to protect the public from contaminated compounded drugs.